PRECISION CARE MANAGEMENT FOR PAYERS
How can you confidently approve molecular tests and targeted treatments while also minimizing burdensome prior authorization processes?
Trapelo knows.
Trapelo aligns the interests of providers, labs, and payers to deliver better care for patients while managing the costs of precision medicine through transparency and real-time automation.
​
Trapelo's FastPath button signals therapies with the highest-level clinical evidence and payer integration to ensure patients get the most appropriate treatment option when time matters most.
“For a majority of payers, cost is the most important factor influencing biomarker coverage, followed closely by clinical validity and utility.”– The Precision Oncology Annual Trend Report, 2016
Trapelo for Payers is:
-
Evidence-based
Assures that that each molecular test ordered through Trapelo meets clinical, evidence-supported standards, so payors can streamline and optimize their prior authorization and reimbursement arrangements.
-
Transparent
Gives payers a real-time window into the precision medicine decision-making process, enabling a review-by-exception process that avoids unnecessary administrative reviews. Trapelo streamlines workflow for practices and expedites the delivery of appropriate, quality care for patients when time matters most.
-
Patient-centered
Ensures patients get the most appropriate tests from preferred labs at the right time in their treatment journey.
-
Collaborative
Some of the nation’s leading cancer centers and community oncologists, along with national and regional molecular testing labs, have endorsed Trapelo’s innovative approach to ensuring the scalable, appropriate use of precision medicine for cancer. ​
Why is oncology care so expensive?
In this episode, retired UnitedHealthcare executive and now Trapelo board member, Dr. Lee Newcomer shares his deep perspective into the complex dynamics behind drug pricing and reimbursement.
Dr. Newcomer began his career as an oncologist. Having witnessed the enormous disparities between cancer care and cost, he made a conscious move to industry and, today, is one of the most recognized change-makers in healthcare today.